New Mexico Attorney General Raúl Torrez announced on Apr. 15 that the state has reached a $2.25 million settlement with Mylan Inc., resolving claims regarding the company’s pricing and business practices related to its EpiPen Auto-Injector products.
The agreement is intended to provide financial relief and consumer protections for New Mexico residents who rely on epinephrine auto-injectors for severe allergic reactions. The case focused on allegations that Mylan used tactics such as delaying generic competition, employing certain patent litigation strategies, and making specific marketing and pricing decisions that violated New Mexico’s consumer protection and antitrust laws.
“This settlement serves as an important protection for New Mexico consumers and families who depend on affordable access to life-saving epinephrine products,” said Attorney General Raúl Torrez. “The New Mexico Department of Justice will continue to fight for fair pricing and transparency in the pharmaceutical industry. We look forward to working with Mylan to raise public awareness of the relief this settlement provides.”
According to the official website, the New Mexico Attorney General fosters trust and accountability through community outreach, supports law enforcement, upholds the rule of law, advances justice through civil litigation and criminal prosecutions, coordinates with local agencies for public safety efforts, provides services across all counties in the state, and serves as chief legal officer.
The broader implications of this settlement highlight ongoing concerns about drug affordability in New Mexico. As noted by Torrez, raising awareness about available relief is part of future steps planned by his office.
